Targeted Therapy For RET-Rearranged Non-Small Cell Lung Cancer: Clinical Development And Future Directions

Approximately 1–2% of unselected patients with Non-small Cell Lung Cancer (NSCLC) harbor RET rearrangements resulting in enhanced cell survival and proliferation. The initial treatment strategy for RET rearranged NSCLC has been multi-target tyrosine kinase inhibition. With overall response rates (OR...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: Ackermann, Christoph Jakob, Stock, Gustavo, Tay, Rebecca, Dawod, Mohammed, Gomes, Fabio, Califano, Raffaele
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove 2019
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6767757/
https://ncbi.nlm.nih.gov/pubmed/31576143
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S171665
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky